|
Title
|
Published
|
Price
|
By
GlobalData
ZIOPHARM Oncology, Inc. (ZIOPHARM Oncology) is health care pharmaceutical company, based in the US. The company manufactures and commercializes small molecular cancer drugs. It develops clinical programs such as, zymafos (palifosfamide, ZIO-201) used
|
May
2013
|
$
250
|
By
GlobalData
Vantage Oncology, Inc. (Vantage Oncology) is a critical oncology service provider, based in the US. The company owns and operates 45 radiation oncology centers in 12 states. It provides treatment for bone, brain, breast, gastrointestinal, gynecologic
|
May
2013
|
$
250
|
By
GlobalData
Neogenix Oncology, Inc. (NOI) is a clinical stage biotechnology company. The company develops therapeutic and diagnostic products for the early detection and treatment of cancer. Its antibody drug candidates and diagnostics are designed to detect and
|
May
2013
|
$
750
|
By
GlobalData
Clovis Oncology, Inc. (Clovis) is a biopharmaceutical company. It undertakes acquiring, developing and commercialization of new anti-cancer agents in the US, Europe and international markets. The company’s product pipeline include CO-101, which is in
|
May
2013
|
$
125
|
By
GlobalData
Neogenix Oncology, Inc. (NOI) is a clinical stage biotechnology company. The company develops therapeutic and diagnostic products for the early detection and treatment of cancer. Its antibody drug candidates and diagnostics are designed to detect and
|
March
2013
|
$
250
|
By
GlobalData
Champions Oncology, Inc. (Champions) is a biotechnology company, based in the US. It offers development of advanced technology solutions and services to personalize the development and use of oncology drugs. The company’s TumorGraft (CTG) Platform is
|
March
2013
|
$
250
|
By
GlobalData
Clovis Oncology, Inc. (Clovis) is a biopharmaceutical company. It undertakes acquiring, developing and commercialization of new anti-cancer agents in the US, Europe and international markets. The company’s product pipeline include CO-101, which is in
|
March
2013
|
$
250
|
By
GlobalData
This comprehensive SWOT profile of Fresenius Kabi Oncology Limited provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of th
|
March
2013
|
$
300
|
By
GlobalData
This comprehensive SWOT profile of CureSearch Children''s Oncology Group provides you with an in-depth strategic analysis of the company''s businesses and operations. The profile will give you a clear and an unbiased view of the company''s key strengths
|
March
2013
|
$
300
|
By
Wildwood Ventures Ltd
The Oncology Partnering Yearbook 2013 report series provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2012. Using these reports, d
|
January
2013
|
$
1495
|
By
GlobalData
Civatech Oncology Inc. (Civatech) is a medical device company. It focuses on the development of novel polymer based devices for the treatment of cancer using localized, low-dose-rate radiation. The company''s product portfolio consists of CivaString a
|
December
2012
|
$
750
|
By
BCC Research
REPORT HIGHLIGHTSThis Oncology Market Research Review provides:An overview of the global market for microRNA diagnostics and therapeutics, with an analysis of the commercial potential of this re...
|
December
2012
|
$
850
|
By
GlobalData
This comprehensive SWOT profile of Champions Oncology, Inc. provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the compa
|
September
2012
|
$
250
|
By
GlobalData
CivaTech Oncology, Inc. is engaged in the development of devices for the treatment of prostate cancer. Its radioactive string device made of polymers is used with brachytherapy needles for radiation therapy treatment.Civatech Oncology Inc. - Medica
|
August
2012
|
$
250
|
By
GlobalData
Light Sciences Oncology, Inc. (LSO) is a pharmaceutical company. It develops drugs for the treatment of solid tumor cancers. Currently, the company is developing light-activated talaporfin sodium, Aptocine, an innovative light-activated drug for the
|
August
2012
|
$
250
|
By
GlobalData
Fresenius Kabi Oncology Limited (Fresenius Kabi) is a drug developing and manufacturing company engages in cancer research and anti-cancer products manufacturing activities. The company develops and manufactures active pharmaceutical ingredients, int
|
August
2012
|
$
250
|
By
Global Markets Direct
Sentinel Oncology Limited – Product Pipeline Review – 2012
Summary
Global Market Direct’s pharmaceuticals report, “Sentinel Oncology Limited - Product Pipeline Review - 2012” provides data on the Sentinel Oncology Limited’s research and develop
|
July
2012
|
$
500
|
By
GlobalData
The US Oncology Network (US Oncology) is a network of community-based oncology physicians. The network includes physicians with a common vision of expanding patient access to high-quality, integrated cancer care in communities. With over 1,000 affili
|
May
2012
|
$
125
|
By
Netscribes
Oncology pharmaceuticals market in India, a leading segment of the overall pharmaceuticals market is the fourth largest in volume and eighth largest in value in the global market. Since cancer is the second largest cause of death in the country, t...
|
April
2012
|
$
795
|
By
GlobalData
Avantogen Oncology, Inc. (Avantogen) is principally engaged in the development and commercialization of oncology drugs. It is formerly known as Innovate Oncology, Inc. It is a subsidiary of Acuvax Limited. Acuvax has 43% stake in the company. Current
|
March
2012
|
$
250
|
By
Global Markets Direct
Global Market Direct’s pharmaceuticals report, “ZIOPHARM Oncology, Inc. - Product Pipeline Review - H2 2011” provides data on the ZIOPHARM Oncology, Inc.’s research and development focus. The report includes information on current developmental pipel
|
November
2011
|
$
500
|
By
ICD Research
Report SummaryICD Research's Oncology Metrics - Company Capsule contains a company overview, key facts, major products and services.SummaryICD Research's Oncology Metri...
|
November
2011
|
$
75
|
By
GlobalData
Neogenix Oncology, Inc. (Neogenix) is a biotechnology company that is engaged in the development of diagnostic and therapeutic products for the treatment of various types of cancers like lung, pancreatic, cervical, prostate and colorectal cancer. The
|
November
2011
|
$
750
|
By
GlobalData
ZIOPHARM Oncology, Inc. (formerly known as EasyWeb, Inc.) is a publicly held US-based company. The company engages in the development and commercialization of small molecular cancer drugs. It primarily focuses on three clinical programs which include
|
September
2011
|
$
250
|
By
Netscribes
Oncology pharmaceuticals market in India, a leading segment of the overall pharmaceuticals market is the fourth largest in volume and eighth largest in value in the global market. Since cancer is the second largest cause of death in the country, t...
|
August
2011
|
$
795
|
By
Global Markets Direct
Global Market Direct’s pharmaceuticals report, ZIOPHARM Oncology, Inc. - Product Pipeline Review - Q2 2011” provides data on the ZIOPHARM Oncology, Inc.’s resea...
|
July
2011
|
$
500
|
By
GlobalData
Avastin (bevacizumab) is a vascular endothelial growth factor (VEGF) receptor inhibitor. It was first approved in 2004 and is used in the treatment of ...
|
May
2011
|
$
500
|
By
Global Markets Direct
Global Market Direct’s pharmaceuticals report, “Sentinel Oncology Limited - Product Pipeline Review - Q1 2011” provides data on the company’s research and dev...
|
March
2011
|
$
500
|
By
Datamonitor
Datamonitor's US Oncology, Inc. - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings, k...
|
March
2011
|
$
125
|
By
Life Science Analytics
provides up to date insight into company’s business description, product information, pipeline details including both information and detailed...
|
March
2011
|
$
750
|
By
Life Science Analytics
provides up to date insight into company’s business description, product information, pipeline details including both information and detailed individual product records....
|
March
2011
|
$
750
|
By
Life Science Analytics
provides up to date insight into company’s business description, product information, pipeline details including both information and detailed individual product records....
|
March
2011
|
$
750
|
By
Life Science Analytics
Report includes a business , tabular representation of the number and percentage of products in each therapeutic indication, all company p...
|
March
2011
|
$
350
|
By
Life Science Analytics
Report includes a business , tabular representation of the number and percentage of products in each therapeutic indication, all company products listed with indication and sta...
|
March
2011
|
$
350
|
By
Life Science Analytics
Report includes a business , tabular representation of the number and percentage of products in each therapeutic indication, all company products listed with indicati...
|
March
2011
|
$
350
|
By
Life Science Analytics
Report includes a business , tabular representation of the number and percentage of products in each therapeutic indication, all company products listed with indication and stage...
|
March
2011
|
$
350
|
By
Life Science Analytics
Report includes a business , tabular representation of the number and percentage of products in each therapeutic indication, all company products listed with indication and stage of de...
|
March
2011
|
$
350
|
By
ICON Group International, Inc.
This econometric study covers the world outlook for hematology and oncology products across more than 200 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country...
|
January
2011
|
$
795
|
By
ICON Group International, Inc.
This econometric study covers the latent demand outlook for hematology and oncology products across the regions of Greater China, including provinces, autonomous regions (Guangxi, Nei Mongol, Ningxia, Xinjiang, Xizang - Tibet), municipaliti...
|
January
2011
|
$
495
|
By
Global Markets Direct
Global Market Direct’s pharmaceuticals report, Boso Clinical Oncology Group – Developmental Therapeutics Review – Q4 2010” provides data on the institute’s research and dev...
|
December
2010
|
$
500
|